Skip to content

To evaluate the analgesic effect of an aqueous extract of Terminalia chebula, a proprietary chromium complex, and their combination in subjects with joint discomfort.

Evaluation of Biomarkers in Patients of Osteoarthritis treated with Terminalia chebula

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/011692
Enrollment
100
Registered
2018-02-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified Health Condition 2: null- Subjects of either gender aged between 40 and 70 years, suffering from joint discomfort for at least 6 months duration, taking only an OTC analgesic medication occasionally.

Interventions

Intervention1: 1.Terminalia chebula (TCE) 2.Proprietary Chromium (PCC) Complex (polyphenolic compunds of Phyllanthus emblica fruit extract and purified Shilajit): Group (A)-1 capsule of TCE 500 mg twi

Sponsors

Nizams Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects of either gender aged between 40 and 70 years, suffering from joint discomfort for at least 6 months duration, taking only an OTC analgesic medication occasionally and meeting the American Rheumatism Association(ARA) functional class I to III and radiological evidence of osteoarthritis, patients who have grade II to IV of the Kellgren and Lawrence scale in the knee joint X-ray and who record baseline pain scores of at least 40 mm on the Visual Analogue Scale(VAS), monitored at baseline visit, subjects agreeing to discontinue any use of analgesics during the study.

Exclusion criteria

Exclusion criteria: Patients with severe osteoarthritis (ARA functional class IV), Patients with radiological grading - Kellgren and Lawrence scale ranging from grade 0 to grade I, patients on alternative system of medicine, any psychiatric disorder or who have been using systemic/intra-articular steroids within 12 weeks and hyaluronic acid in the last 9 months, or potential candidates for imminent joint replacement, Patients with uncontrolled hypertension or diabetes, hepatic or renal impairment, pregnant or lactating females, or with a recent trauma of the involved knee.

Design outcomes

Primary

MeasureTime frame
Modified Western Ontario and McMaster Universities (mWOMAC) Index is a disease specific outcome measure for osteoarthritis. It has three subscales assessing, Pain â??A, Stiffness-B and Physical Function for Disability-C. Primary outcome is the reduction in modified WOMAC total score (A+B+C) from baseline to the end of treatment at week 12.Timepoint: week 4, week 8 and week 12.

Secondary

MeasureTime frame
VAS based assessment of Pain,Disability, and Stiffness subscales. Knee Swelling Index as measured by signal joint knee circumference. Use of rescue medication in all treatment groups. Physician global assessment-characterized by 5 categories:Excellent- complete relief of symptoms;Goodâ??partial relief of symptoms;Fairâ??minimal relief of symptoms;poorâ??no relief of symptoms;very poorâ??worsening of symptomsTimepoint: week 4, week 8 and week 12.

Countries

India

Contacts

Public ContactN Chandrasekhar

Nizams Institute of Medical Sciences

csnpru@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026